Donor and recipient selection for islet transplantation

Cristiana Rastellini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Today there are approximately 130 million people with diabetes, and the incidence is rising among all age groups. Insulin treatment can maintain the functionality necessary to keep these patients alive, but it cannot prevent the evolution of the disease. Clinical islet transplantation offers the promise of curing in type I diabetes mellitus by an injection of cellular grafts into the liver, freeing the patient from daily insulin injections and preventing potential secondary complications. In a recent Canadian experience, a series of patients receiving islet grafts in conjunction with a steroid-free immunosuppression achieved sustained insulin independence. Donor selection is at the present time based on whole pancreas transplantation donor criteria, but experimental findings on age, pancreatic tissue fibrosis and non-heart-beating donors clearly demonstrate the bright prospects for the expansion of islet donor sources. Research in the islet transplantation field is currently concentrating on reversing diabetes in nonuremic type I patients. Strict recipient inclusion criteria have been proposed by the experienced Canadian group and the Immune Tolerance Network islet trial. At this stage, determination of major guidelines is the most important condition to reproduce the recently reported successful results, and more consistently demonstrate the feasibility of this minimally invasive procedure for the treatment of diabetes.

Original languageEnglish (US)
Pages (from-to)196-201
Number of pages6
JournalCurrent Opinion in Organ Transplantation
Volume7
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Donor Selection
Islets of Langerhans Transplantation
Tissue Donors
Insulin
Transplants
Pancreas Transplantation
Immune Tolerance
Injections
Type 1 Diabetes Mellitus
Immunosuppression
Fibrosis
Age Groups
Steroids
Guidelines
Liver
Incidence
Therapeutics
Research

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Donor and recipient selection for islet transplantation. / Rastellini, Cristiana.

In: Current Opinion in Organ Transplantation, Vol. 7, No. 2, 2002, p. 196-201.

Research output: Contribution to journalArticle

Rastellini, Cristiana. / Donor and recipient selection for islet transplantation. In: Current Opinion in Organ Transplantation. 2002 ; Vol. 7, No. 2. pp. 196-201.
@article{a388e3aafcfa4add9203d72a526bbe28,
title = "Donor and recipient selection for islet transplantation",
abstract = "Today there are approximately 130 million people with diabetes, and the incidence is rising among all age groups. Insulin treatment can maintain the functionality necessary to keep these patients alive, but it cannot prevent the evolution of the disease. Clinical islet transplantation offers the promise of curing in type I diabetes mellitus by an injection of cellular grafts into the liver, freeing the patient from daily insulin injections and preventing potential secondary complications. In a recent Canadian experience, a series of patients receiving islet grafts in conjunction with a steroid-free immunosuppression achieved sustained insulin independence. Donor selection is at the present time based on whole pancreas transplantation donor criteria, but experimental findings on age, pancreatic tissue fibrosis and non-heart-beating donors clearly demonstrate the bright prospects for the expansion of islet donor sources. Research in the islet transplantation field is currently concentrating on reversing diabetes in nonuremic type I patients. Strict recipient inclusion criteria have been proposed by the experienced Canadian group and the Immune Tolerance Network islet trial. At this stage, determination of major guidelines is the most important condition to reproduce the recently reported successful results, and more consistently demonstrate the feasibility of this minimally invasive procedure for the treatment of diabetes.",
author = "Cristiana Rastellini",
year = "2002",
doi = "10.1097/00075200-200206000-00016",
language = "English (US)",
volume = "7",
pages = "196--201",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Donor and recipient selection for islet transplantation

AU - Rastellini, Cristiana

PY - 2002

Y1 - 2002

N2 - Today there are approximately 130 million people with diabetes, and the incidence is rising among all age groups. Insulin treatment can maintain the functionality necessary to keep these patients alive, but it cannot prevent the evolution of the disease. Clinical islet transplantation offers the promise of curing in type I diabetes mellitus by an injection of cellular grafts into the liver, freeing the patient from daily insulin injections and preventing potential secondary complications. In a recent Canadian experience, a series of patients receiving islet grafts in conjunction with a steroid-free immunosuppression achieved sustained insulin independence. Donor selection is at the present time based on whole pancreas transplantation donor criteria, but experimental findings on age, pancreatic tissue fibrosis and non-heart-beating donors clearly demonstrate the bright prospects for the expansion of islet donor sources. Research in the islet transplantation field is currently concentrating on reversing diabetes in nonuremic type I patients. Strict recipient inclusion criteria have been proposed by the experienced Canadian group and the Immune Tolerance Network islet trial. At this stage, determination of major guidelines is the most important condition to reproduce the recently reported successful results, and more consistently demonstrate the feasibility of this minimally invasive procedure for the treatment of diabetes.

AB - Today there are approximately 130 million people with diabetes, and the incidence is rising among all age groups. Insulin treatment can maintain the functionality necessary to keep these patients alive, but it cannot prevent the evolution of the disease. Clinical islet transplantation offers the promise of curing in type I diabetes mellitus by an injection of cellular grafts into the liver, freeing the patient from daily insulin injections and preventing potential secondary complications. In a recent Canadian experience, a series of patients receiving islet grafts in conjunction with a steroid-free immunosuppression achieved sustained insulin independence. Donor selection is at the present time based on whole pancreas transplantation donor criteria, but experimental findings on age, pancreatic tissue fibrosis and non-heart-beating donors clearly demonstrate the bright prospects for the expansion of islet donor sources. Research in the islet transplantation field is currently concentrating on reversing diabetes in nonuremic type I patients. Strict recipient inclusion criteria have been proposed by the experienced Canadian group and the Immune Tolerance Network islet trial. At this stage, determination of major guidelines is the most important condition to reproduce the recently reported successful results, and more consistently demonstrate the feasibility of this minimally invasive procedure for the treatment of diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0036055590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036055590&partnerID=8YFLogxK

U2 - 10.1097/00075200-200206000-00016

DO - 10.1097/00075200-200206000-00016

M3 - Article

AN - SCOPUS:0036055590

VL - 7

SP - 196

EP - 201

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 2

ER -